Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 4
2013 7
2014 14
2015 11
2016 16
2017 15
2018 24
2019 30
2020 34
2021 49
2022 70
2023 44
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Results by year

Filters applied: . Clear all
Page 1
Immunology and immunotherapy of cholangiocarcinoma.
Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, Wang XW. Greten TF, et al. Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):349-365. doi: 10.1038/s41575-022-00741-4. Epub 2023 Jan 25. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36697706 Review.
Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in the Western world but is rising globally. ...Immunotherapy has emerged as a potent strategy for many different types of cancer and has shown efficacy in combination with chemotherapy …
Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in the Western world but is rising globally. …
Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Kelley RK, et al. J Hepatol. 2020 Feb;72(2):353-363. doi: 10.1016/j.jhep.2019.10.009. J Hepatol. 2020. PMID: 31954497 Review.
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. ...Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NT …
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. ...Compared to …
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Abou-Alfa GK, et al. Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416072 Free PMC article. Clinical Trial.
BACKGROUND: Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase 3 study was to assess the effic …
BACKGROUND: Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangioc …
Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, Gores GJ. Ilyas SI, et al. Nat Rev Clin Oncol. 2023 Jul;20(7):470-486. doi: 10.1038/s41571-023-00770-1. Epub 2023 May 15. Nat Rev Clin Oncol. 2023. PMID: 37188899 Free PMC article. Review.
In the past 5 years, important advances have been made in the scientific understanding and clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA has been characterized and tumour subsets with distinct immune microenvironments have been defin …
In the past 5 years, important advances have been made in the scientific understanding and clinical management of cholangiocarcinoma …
Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
Merters J, Lamarca A. Merters J, et al. J Hepatol. 2023 Mar;78(3):652-657. doi: 10.1016/j.jhep.2022.11.005. Epub 2022 Nov 15. J Hepatol. 2023. PMID: 36400328 Review.
In this setting, chemotherapy with cisplatin and gemcitabine (with durvalumab) followed by second-line FOLFOX is the cornerstone of treatment. Targeted therapies for tumours harbouring FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, NTRK fusions and/or HER2 (ERBB2) am …
In this setting, chemotherapy with cisplatin and gemcitabine (with durvalumab) followed by second-line FOLFOX is the cornerstone of treatmen …
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, Llovet JM, Thung SN, Tsankov AM, Sia D. Martin-Serrano MA, et al. Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18. Gut. 2023. PMID: 35584893 Free PMC article.
OBJECTIVE: The diversity of the tumour microenvironment (TME) of intrahepatic cholangiocarcinoma (iCCA) has not been comprehensively assessed. ...Among the non-inflamed classes, the desert-like class (~20%) harbours the lowest immune infiltration with abundant regul …
OBJECTIVE: The diversity of the tumour microenvironment (TME) of intrahepatic cholangiocarcinoma (iCCA) has not been comprehen …
Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue.
Brandi G, Deiana C, Galvani L, Palloni A, Ricci AD, Rizzo A, Tavolari S. Brandi G, et al. Front Oncol. 2023 Apr 24;13:1137510. doi: 10.3389/fonc.2023.1137510. eCollection 2023. Front Oncol. 2023. PMID: 37168376 Free PMC article. Review.
Despite representing some of the most common and investigated molecular changes in intrahepatic cholangiocarcinoma (iCCA), the prognostic role of FGFR and IDH1/2 alterations still remains an open question. ...Despite the overall poor quality of current availa …
Despite representing some of the most common and investigated molecular changes in intrahepatic cholangiocarcinoma (iCCA), the …
How I treat biliary tract cancer.
Lamarca A, Edeline J, Goyal L. Lamarca A, et al. ESMO Open. 2022 Feb;7(1):100378. doi: 10.1016/j.esmoop.2021.100378. Epub 2022 Jan 13. ESMO Open. 2022. PMID: 35032765 Free PMC article. Review.
Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Unfortunately relapse rate remains high, and better adjuvant strategies are urgently required. ...Targeted therapies, including therapies for …
Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Un …
IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives.
Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. Crispo F, et al. Molecules. 2020 Aug 18;25(16):3754. doi: 10.3390/molecules25163754. Molecules. 2020. PMID: 32824685 Free PMC article. Review.
Cholangiocarcinoma is a primary malignancy of the biliary tract characterized by late and unspecific symptoms, unfavorable prognosis, and few treatment options. ...Thus, its accumulation produces changes in the expression of several key genes involved in cell differentiati …
Cholangiocarcinoma is a primary malignancy of the biliary tract characterized by late and unspecific symptoms, unfavorable prognosis, …
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H. Chang S, et al. Exp Mol Med. 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. Exp Mol Med. 2019. PMID: 31221981 Free PMC article. Review.
Table 1 Cancer driver genes involved in epigenetics Pathways involved in epigenetics Driver genes Tumor suppressor/oncogene prediction (by 20/20+(a)) Approved name Activity Cancer type(b) Other driver genes in this pathways Histone modification KDM6A tsg Lysine demethylase 6A, UT …
Table 1 Cancer driver genes involved in epigenetics Pathways involved in epigenetics Driver genes Tumor suppressor/oncogene prediction (by 2 …
309 results